Clinical Trials Logo

Clinical Trial Summary

This protocol for compassionate use combines 2 different ways of fighting disease: antibodies and T cells. Both antibodies and T cells have been used to treat patients with cancers, and both have shown promise, but neither alone has been sufficient to cure most patients. This protocol combines both T cells and antibodies to create a more effective treatment. The investigational treatment is called autologous T lymphocyte chimeric antigen receptor cells targeted against the CD30 antigen (ATLCAR.CD30) administration. Prior studies have shown that a new gene can be put into T cells and will increase their ability to recognize and kill cancer cells. The new gene that is put in the T cells in this study makes a piece of an antibody called anti-CD30. This antibody sticks to leukemia cells because they have a substance on the outside of the cells called CD30. For this protocol, the anti-CD30 antibody has been changed so that instead of floating free in the blood part of it is now joined to the T cells. When an antibody is joined to a T cell in this way it is called a chimeric receptor. These CD30 chimeric (combination) receptor-activated T cells seem to kill some of the tumor, but they do not last very long in the body and so their chances of fighting the cancer are unknown. The primary purpose of this protocol is to treat a single patient with a second dose of ATLCAR.CD30 T cells.


Clinical Trial Description

Lymphodepleting Chemotherapy: The patient will receive a lymphodepleting regimen of bendamustine 70mg/m2/day over 3 consecutive days and fludarabine 30mg/m2/day over 2 consecutive days. Bendamustine and fludarabine will be administered concomitantly. Dose reduction of bendamustine may occur per treating physician discretion based on prior toxicities and the clinical status of the patient. Administration of ATLCAR.CD30 T cells: Post lymphodepletion, if the patient meets eligibility criteria for cellular therapy, then will receive ATLCAR.CD30 T cells within 2-14 days after completing the pre-conditioning chemotherapy regimen. We will administer ATLCAR.CD30 T cells post lymphodepletion at a dose of 2 x 10^8 cells/m2. Duration of Therapy: Therapy under this compassionate use protocol involves 1 infusion of ATLCAR.CD30 cells. Duration of Follow-up: The patient will be followed for up to 15 years for replication-competent retrovirus evaluation or until death, whichever occurs first. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03914885
Study type Expanded Access
Source UNC Lineberger Comprehensive Cancer Center
Contact
Status No longer available
Phase

See also
  Status Clinical Trial Phase
Recruiting NCT04653649 - CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma. Phase 1/Phase 2
Recruiting NCT04636255 - Physical Capacity in Hodgkin Lymphoma Survivors N/A
Not yet recruiting NCT06421987 - Cardiopulmonary Function and Cerebral Blood Flow in Hodgkin Lymphoma Survivors
Recruiting NCT05597761 - Immunogenicity of COVID-19 Vaccination in Autologous HSCT or CAR-T Cells Recipients
Active, not recruiting NCT03535948 - Elderly Hodgkin Lymphoma Patients Treated With Chemoradiotherapy
Completed NCT03155425 - PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's Lymphoma Phase 2
Recruiting NCT03260101 - Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 Study
Recruiting NCT04776265 - RWE of Brentuximab Vedotin Consolidation in Patients With RR HL Who Receive Salvage Chemotherapy and ASCT
Recruiting NCT04378647 - BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant Phase 2
Recruiting NCT04758650 - Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions, Cardiovascular Atherosclerosis, Syndrome With Abnormal Immune Activation and sarcoïdosis Phase 2
Recruiting NCT05137886 - PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma Phase 2
Recruiting NCT05798897 - Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma Phase 1
Completed NCT04292626 - Molecular Imaging of Lymphoma Using Labeled Technetium-99m 1-Thio-D-Glucose Phase 1
Active, not recruiting NCT04268706 - Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT) Phase 2
Recruiting NCT04638790 - First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1) Phase 3
Completed NCT01578967 - Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma N/A